nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—MAOA—Clearance of dopamine—SLC6A3—Gilles de la Tourette syndrome	0.0677	0.0831	CbGpPWpGaD
Naratriptan—MAOA—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.0536	0.0659	CbGpPWpGaD
Naratriptan—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0309	0.0379	CbGpPWpGaD
Naratriptan—HTR1F—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0274	0.0336	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0226	0.0277	CbGpPWpGaD
Naratriptan—HTR1F—nervous system—Gilles de la Tourette syndrome	0.02	0.119	CbGeAlD
Naratriptan—HTR1F—central nervous system—Gilles de la Tourette syndrome	0.0193	0.115	CbGeAlD
Naratriptan—HTR1F—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0192	0.0236	CbGpPWpGaD
Naratriptan—HTR1F—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0187	0.0229	CbGpPWpGaD
Naratriptan—HTR1D—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0175	0.0215	CbGpPWpGaD
Naratriptan—HTR1F—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0174	0.0214	CbGpPWpGaD
Naratriptan—Sumatriptan—DRD2—Gilles de la Tourette syndrome	0.0173	1	CrCbGaD
Naratriptan—HTR1B—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0171	0.021	CbGpPWpGaD
Naratriptan—HTR1F—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0162	0.0199	CbGpPWpGaD
Naratriptan—HTR1F—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0157	0.0193	CbGpPWpGaD
Naratriptan—HTR1F—brain—Gilles de la Tourette syndrome	0.0153	0.091	CbGeAlD
Naratriptan—HTR1F—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0146	0.018	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0144	0.0177	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0141	0.0173	CbGpPWpGaD
Naratriptan—HTR1A—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0131	0.016	CbGpPWpGaD
Naratriptan—HTR1D—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0123	0.0151	CbGpPWpGaD
Naratriptan—HTR1F—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0122	0.015	CbGpPWpGaD
Naratriptan—HTR1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.012	0.0148	CbGpPWpGaD
Naratriptan—HTR1D—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0119	0.0147	CbGpPWpGaD
Naratriptan—HTR1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0117	0.0144	CbGpPWpGaD
Naratriptan—HTR1D—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0111	0.0137	CbGpPWpGaD
Naratriptan—HTR1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0109	0.0134	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0108	0.0132	CbGpPWpGaD
Naratriptan—HTR1D—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0103	0.0127	CbGpPWpGaD
Naratriptan—HTR1F—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0102	0.0126	CbGpPWpGaD
Naratriptan—HTR1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0101	0.0124	CbGpPWpGaD
Naratriptan—HTR1D—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.01	0.0123	CbGpPWpGaD
Naratriptan—HTR1B—midbrain—Gilles de la Tourette syndrome	0.00999	0.0593	CbGeAlD
Naratriptan—HTR1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00983	0.0121	CbGpPWpGaD
Naratriptan—HTR1D—midbrain—Gilles de la Tourette syndrome	0.00967	0.0574	CbGeAlD
Naratriptan—HTR1D—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00935	0.0115	CbGpPWpGaD
Naratriptan—HTR1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00918	0.0113	CbGpPWpGaD
Naratriptan—HTR1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00916	0.0112	CbGpPWpGaD
Naratriptan—HTR1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00891	0.0109	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00855	0.0105	CbGpPWpGaD
Naratriptan—HTR1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0083	0.0102	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0083	0.0102	CbGpPWpGaD
Naratriptan—HTR1B—nervous system—Gilles de la Tourette syndrome	0.00821	0.0488	CbGeAlD
Naratriptan—HTR1A—midbrain—Gilles de la Tourette syndrome	0.00806	0.0479	CbGeAlD
Naratriptan—HTR1D—nervous system—Gilles de la Tourette syndrome	0.00795	0.0472	CbGeAlD
Naratriptan—HTR1B—central nervous system—Gilles de la Tourette syndrome	0.00791	0.047	CbGeAlD
Naratriptan—HTR1D—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00779	0.00957	CbGpPWpGaD
Naratriptan—HTR1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00771	0.00947	CbGpPWpGaD
Naratriptan—HTR1D—central nervous system—Gilles de la Tourette syndrome	0.00766	0.0455	CbGeAlD
Naratriptan—HTR1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00763	0.00937	CbGpPWpGaD
Naratriptan—HTR1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00749	0.0092	CbGpPWpGaD
Naratriptan—MAOA—midbrain—Gilles de la Tourette syndrome	0.00736	0.0437	CbGeAlD
Naratriptan—HTR1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00698	0.00857	CbGpPWpGaD
Naratriptan—HTR1A—nervous system—Gilles de la Tourette syndrome	0.00663	0.0394	CbGeAlD
Naratriptan—HTR1D—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00655	0.00804	CbGpPWpGaD
Naratriptan—HTR1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00641	0.00788	CbGpPWpGaD
Naratriptan—HTR1A—central nervous system—Gilles de la Tourette syndrome	0.00638	0.0379	CbGeAlD
Naratriptan—HTR1B—brain—Gilles de la Tourette syndrome	0.00628	0.0373	CbGeAlD
Naratriptan—HTR1D—brain—Gilles de la Tourette syndrome	0.00608	0.0361	CbGeAlD
Naratriptan—MAOA—nervous system—Gilles de la Tourette syndrome	0.00605	0.036	CbGeAlD
Naratriptan—MAOA—central nervous system—Gilles de la Tourette syndrome	0.00583	0.0346	CbGeAlD
Naratriptan—HTR1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00581	0.00714	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00541	0.00665	CbGpPWpGaD
Naratriptan—HTR1A—brain—Gilles de la Tourette syndrome	0.00507	0.0301	CbGeAlD
Naratriptan—HTR1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00489	0.006	CbGpPWpGaD
Naratriptan—MAOA—brain—Gilles de la Tourette syndrome	0.00463	0.0275	CbGeAlD
Naratriptan—HTR1F—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.004	0.00491	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00388	0.00477	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00371	0.00456	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00362	0.00444	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0036	0.00443	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00336	0.00412	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00318	0.00391	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00309	0.00379	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00288	0.00353	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00256	0.00314	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00251	0.00308	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00248	0.00305	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00243	0.00299	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00242	0.00297	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00237	0.00292	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00235	0.00289	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00235	0.00289	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00235	0.00289	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00232	0.00285	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00231	0.00284	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0023	0.00283	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00227	0.00278	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00226	0.00277	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00219	0.00269	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00215	0.00264	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0021	0.00258	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00203	0.0025	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00201	0.00247	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00199	0.00245	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00197	0.00243	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00197	0.00242	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00193	0.00237	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00191	0.00234	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00185	0.00228	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00184	0.00226	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.0018	0.00221	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.0018	0.00221	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00177	0.00217	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00173	0.00212	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00172	0.00211	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00168	0.00206	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0016	0.00197	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00155	0.0019	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00153	0.00188	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00152	0.00186	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00152	0.00186	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0015	0.00185	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0015	0.00185	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00147	0.00181	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00147	0.00181	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00147	0.00181	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0014	0.00172	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00137	0.00169	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00137	0.00168	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00137	0.00168	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00133	0.00163	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—HDC—Gilles de la Tourette syndrome	0.0013	0.0016	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00129	0.00158	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00126	0.00155	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00124	0.00153	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00124	0.00152	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00121	0.00148	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00116	0.00142	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00112	0.00138	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00112	0.00138	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00112	0.00138	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00104	0.00128	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000981	0.0012	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000961	0.00118	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000961	0.00118	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000875	0.00108	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000867	0.00106	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000857	0.00105	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00085	0.00104	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000832	0.00102	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000795	0.000976	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000792	0.000972	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000787	0.000967	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000778	0.000956	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000775	0.000952	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000772	0.000948	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000756	0.000928	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000734	0.000902	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000732	0.000899	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000719	0.000883	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000713	0.000875	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000704	0.000864	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000664	0.000816	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000653	0.000802	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000634	0.000778	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000593	0.000728	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000591	0.000725	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000576	0.000707	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000554	0.000681	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000543	0.000667	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000536	0.000659	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000504	0.000618	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000493	0.000605	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00047	0.000577	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000465	0.000571	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00046	0.000565	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000456	0.00056	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000446	0.000548	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000425	0.000522	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000416	0.000511	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000414	0.000508	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000376	0.000461	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00035	0.00043	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00034	0.000418	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000317	0.000389	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000297	0.000365	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000291	0.000358	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000222	0.000272	CbGpPWpGaD
